Abstract
Hyaluronan receptors (CD44, RHAMM) are over-expressed in a wide variety of cancers including bladder and ovarian tumors. Based on this rationale, a hyaluronic acid paclitaxel conjugate, ONCOFID™-P, was developed for the treatment of refractory bladder cancer and peritoneal carcinosis. ONCOFID™-P has demonstrated improved in vitro and in vivo efficacy in hyaluronan receptor-positive tumor models and a favorable toxicity profile in rodents. It has been investigated in 15 patients with refractory bladder cancer by intravesical instillation, showing promising antitumor efficacy with 60 % of treated patients achieving a complete response. As a consequence, phase II studies with ONCOFID™-P are ongoing in six European countries. In addition, phase I studies have been initiated investigating the maximum tolerated dose (MTD) and the safety profile of ONCOFID™-P following IP infusion in patients affected by intraperitoneal carcinosis in ovarian, breast, stomach, bladder and colon cancer.
Keywords: Hyaluronic acid, paclitaxel, anticancer, conjugate, bladder cancer, peritoneal carcinosis, colon cancer, antitumor, polysaccharide, drug conjugate
Current Bioactive Compounds
Title: ONCOFID™-P a Hyaluronic Acid Paclitaxel Conjugate for the Treatment of Refractory Bladder Cancer and Peritoneal Carcinosis
Volume: 7 Issue: 1
Author(s): Monica Campisi and Davide Renier
Affiliation:
Keywords: Hyaluronic acid, paclitaxel, anticancer, conjugate, bladder cancer, peritoneal carcinosis, colon cancer, antitumor, polysaccharide, drug conjugate
Abstract: Hyaluronan receptors (CD44, RHAMM) are over-expressed in a wide variety of cancers including bladder and ovarian tumors. Based on this rationale, a hyaluronic acid paclitaxel conjugate, ONCOFID™-P, was developed for the treatment of refractory bladder cancer and peritoneal carcinosis. ONCOFID™-P has demonstrated improved in vitro and in vivo efficacy in hyaluronan receptor-positive tumor models and a favorable toxicity profile in rodents. It has been investigated in 15 patients with refractory bladder cancer by intravesical instillation, showing promising antitumor efficacy with 60 % of treated patients achieving a complete response. As a consequence, phase II studies with ONCOFID™-P are ongoing in six European countries. In addition, phase I studies have been initiated investigating the maximum tolerated dose (MTD) and the safety profile of ONCOFID™-P following IP infusion in patients affected by intraperitoneal carcinosis in ovarian, breast, stomach, bladder and colon cancer.
Export Options
About this article
Cite this article as:
Campisi Monica and Renier Davide, ONCOFID™-P a Hyaluronic Acid Paclitaxel Conjugate for the Treatment of Refractory Bladder Cancer and Peritoneal Carcinosis, Current Bioactive Compounds 2011; 7 (1) . https://dx.doi.org/10.2174/157340711795163848
DOI https://dx.doi.org/10.2174/157340711795163848 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification
Current Pharmaceutical Design AFM-Based Single Molecule Techniques: Unraveling the Amyloid Pathogenic Species
Current Pharmaceutical Design Polysaccharide Based Formulations for Mucosal Drug Delivery: A Review
Current Pharmaceutical Design Aminolevulinic Acid Derivatives and Liposome Delivery as Strategies for Improving 5-Aminolevulinic Acid- Mediated Photodynamic Therapy
Current Medicinal Chemistry Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance
Current Medicinal Chemistry From Ocean to Bedside: the Therapeutic Potential of Molluscan Hemocyanins
Current Medicinal Chemistry Evaluation of the Cytotoxic and Pro-Apoptotic Activities of Eu(III) Complexes with Appended DNA Intercalators in a Panel of Human Malignant Cell Lines
Medicinal Chemistry The Vitamin D/CYP24A1 Story in Cancer
Anti-Cancer Agents in Medicinal Chemistry miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance
Current Gene Therapy The Adenine Nucleotide Translocator: A New Potential Chemotherapeutic Target
Current Drug Targets Multicomponent Reactions in Antimitotic Drug Discovery
Current Topics in Medicinal Chemistry DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy
Current Cancer Drug Targets Anti-Angiogenic Peptides for Cancer Therapeutics
Current Pharmaceutical Biotechnology Epigenetic Control Using Natural Products and Synthetic Molecules
Current Medicinal Chemistry Extrahepatic Targets and Cellular Reactivity of Drug Metabolites
Current Medicinal Chemistry Chemistry and Theranostic Applications of Radiolabeled Nanoparticles for Cardiovascular, Oncological, and Pulmonary Research
Current Topics in Medicinal Chemistry The Human Indoleamine 2,3-Dioxygenase Gene and Related Human Genes
Current Drug Metabolism Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application
Current Vascular Pharmacology Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments
Current Drug Metabolism Current Status and Future Perspectives of Chemoprevention in Head and Neck Cancer
Current Cancer Drug Targets